BioCity Biopharma recently announced positive results from the ongoing 2-SUCCEED trial.

The use of SC0062 resulted in clinically meaningful and statistically significant reduction in proteinuria in patients with immunoglobulin A (IgA) nephropathy (IgAN). The ageing global population will lead to an increase in the prevalence of chronic kidney disease (CKD), leading to an expansion of the market as well as a growing need for more therapeutic options. Key opinion leaders interviewed by GlobalData have mentioned that a drug that specifically shows enhanced efficacy in CKD patients will most likely receive breakthrough or fast track designations and gain market share. GlobalData believes that this study could be of high clinical value to nephrologists who are seeking an optimal treatment of choice for IgAN patients.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

SC0062 is an endothelin 1 receptor antagonist. 2-SUCCEED is an ongoing, randomised, double-blind, placebo-controlled Phase II trial to assess the safety and efficacy of SC0062 for CKD. The results showed that SC0062 met the primary endpoint of reducing proteinuria in IgAN patients. Oedema was not observed in SC0062-treated patients. Additionally, for participants who were on a sodium-glucose co-transporter 2 (SGLT2) inhibitor in the trial, the combination of SC0062 and an SGLT2 inhibitor had a favourable safety profile.

IgAN is a common cause of CKD and kidney failure. CKD is a condition characterised by a gradual loss of kidney function. This leads to the accumulation of excess fluid and waste in the body. In the early stages, CKD is a largely asymptomatic condition.

BioCity is a biotechnology research company headquartered in Wuxi, Jiangsu, China, that develops biological mechanisms in the fields of tumour signal transduction pathways and cellular immune responses for tumours and CKD. According to GlobalData’s PIC drug database, there are four endothelin 1 receptor antagonists in development for CKD: AstraZeneca’s zibotentan plus dapagliflozin combination in Phase III, BioCity’s SC0062 in Phase II, Gmax BioPharm’s GMA-131 in preclinical, and Asahi Kasei’s endothelin A receptor antagonist, also in preclinical.

See Also:

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.